#ESMO26 | TROPHY-U-01 Cohort 7: Sacituzumab govitecan + EV + zimberelimab in advanced urothelial cancer.
Promising early activity: ORR 81%, median PFS 19.3 months, and OS not reached.
@SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily
46 views · 0 likes · 1 repost · 0 replies
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.orgSource: Martin ZapataLaguado · x.com